Skip to content
Manufacture of pharmaceutical products
KZActiveBIN 120740008946
Plans from 2 000 ₸ a month
No entries in risk registers
Registers checked: 18
To risks

ТОО "BEST PHARMA"

Director
Иманалиева Балнұр Ермекқызы
Incorporated
16.07.2012
Address
Шымкент ул. КУРМАНБЕКОВА, зд. 2
РНН
582300031171

This is a company preview

Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.

The pack is not a subscription, its checks last 30 days

Risks

0/18

This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.

Procurement signals

Court cases

Arrests & encumbrances

Enforcement proceedings

Certificates

Licenses and permits

Profile

Summary

Full name
ТОВАРИЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "BEST PHARMA"
BIN
120740008946
Status
Active
Director
Иманалиева Балнұр Ермекқызы
Registration date
16.07.2012
Activity
Производство фармацевтических препаратов
Legal address
Шымкент ул. КУРМАНБЕКОВА, зд. 2

In government contracts over 2 years

VAT payer
Yes, since 09.01.2019
КАТО
791910000
РНН
582300031171
КФС
Собственность предприятий без государственного и иностранного участия
КСЕ
Национальные частные нефинансовые корпорации – ОПП
Company size
Малые предприятия
Employees
от 6 до 10 чел.

Has changed

Procurement role
Поставщик

Activities

2
21201primary

Производство фармацевтических препаратов

Secondary

  • 47731Розничная торговля фармацевтическими товарами в специализированных магазинах, являющихся торговыми объектами, с торговой площадью менее 2000 кв.м
Download

Contacts

Change history

Financials

Tax payments

6

By year · ₸

2026
15.8M
2025
15.7M+230%
2024
4.7M+17%
2023
4M-72%
2022
14.5M+1827%
2021
751.7K
·15.8M
2026year to date
+230%15.7M
2025
+17%4.7M
2024
-72%4M
2023
+1827%14.5M
2022
·751.7K
2021
2026
Tax paid15,819,174 ₸
Penalty122,700 ₸
Fine0 ₸
VAT refund0 ₸
2025
Tax paid15,661,054 ₸
Penalty1,276,552 ₸
Fine268,083 ₸
VAT refund0 ₸
2024
Tax paid4,744,340 ₸
Penalty163,500 ₸
Fine203,475 ₸
VAT refund0 ₸
2023
Tax paid4,045,943 ₸
Penalty902,613 ₸
Fine25,875 ₸
VAT refund0 ₸
2022
Tax paid14,486,142 ₸
Penalty1,503,000 ₸
Fine53,703 ₸
VAT refund0 ₸
2021
Tax paid751,732 ₸
Penalty0 ₸
Fine0 ₸
VAT refund0 ₸
Estimated taxable profit

Estimate: corporate income tax ÷ 0%. Not a filing and not revenue — the taxable profit implied by the corporate income tax paid. Actual profit differs by deductions, carried-forward losses and reduced rates.

Download

Financial statements

Premium

Public contracts

What it sells and where

Samruk-Kazyna procurement

Tender bids

Procurement as a customer

Assets

Bank accounts

Management & owners

Leadership

1
  • ИБ

    Иманалиева Балнұр Ермекқызы

    Director

Download

Founders

Accreditations

Employees

Affiliated companies

Premium

Director's involvement in other legal entities

Branches

Relations & mentions

Company networks

Premium

Similar companies

Media mentions

Company summary

ТОО "BEST PHARMA" (BIN 120740008946) is an active legal entity in Шымкент, registered in 2012 (14 years on the market). Primary activity — производство фармацевтических препаратов. Per open government registries as of November 8, 2026: 53 government contracts on Портал государственных закупок РК (goszakup.gov.kz) worth 558,126,352 ₸. Automated screening of open registries found no risk indicators for "BEST PHARMA". Director on record — Иманалиева Балнұр Ермекқызы. Data current as of November 8, 2026.

Information is aggregated from open government registries of Kazakhstan: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is indexed automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the corresponding facts. This is reference information and does not replace an official extract. Learn more about the methodology and sources — SafeDeal editorial policy.